Literature DB >> 16905527

Phylogenetic background and carriage of pathogenicity island-like domains in relation to antibiotic resistance profiles among Escherichia coli urosepsis isolates.

Véronique Houdouin1, Stéphane Bonacorsi, Philippe Bidet, Martine Bingen-Bidois, Dominique Barraud, Edouard Bingen.   

Abstract

We studied 100 well-characterized E. coli blood isolates from patients with urosepsis for their susceptibility to nalidixic acid, ampicillin and trimethoprim-sulfamethoxazole, according to prevalence of virulence factors, phylogenetic groups and subgroups, PAI II(J96)-like domains (determined by physical linkage of cnf1, hly and hra) and PAI I(CFT073)-like domains (determined by physical linkage of papGII to the hly locus). Nalidixic acid resistance was associated with a lower prevalence of sfa/foc, K1 antigen, pathogenicity island II(J96)-like domains, subgroup B2/I and a shift towards group A.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16905527     DOI: 10.1093/jac/dkl326

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  14 in total

1.  Cyclomodulins in urosepsis strains of Escherichia coli.

Authors:  Damien Dubois; Julien Delmas; Anne Cady; Frédéric Robin; Adeline Sivignon; Eric Oswald; Richard Bonnet
Journal:  J Clin Microbiol       Date:  2010-04-07       Impact factor: 5.948

2.  Virulence genotype and phylogenetic groups in relation to Chinese herb resistance among Escherichia coli from patients with acute pyelonephritis.

Authors:  YanQing Tong; ShuQing Sun; Ying Chi
Journal:  Afr J Tradit Complement Altern Med       Date:  2014-04-03

3.  Clinical factors associated with shock in bacteremic UTI.

Authors:  Katsumi Shigemura; Kazushi Tanaka; Kayo Osawa; Sochi Arakawa; Hideaki Miyake; Masato Fujisawa
Journal:  Int Urol Nephrol       Date:  2013-04-25       Impact factor: 2.370

4.  Virulence potential of Escherichia coli isolates from skin and soft tissue infections.

Authors:  Ziva Petkovsek; Kristina Elersic; Marija Gubina; Darja Zgur-Bertok; Marjanca Starcic Erjavec
Journal:  J Clin Microbiol       Date:  2009-04-08       Impact factor: 5.948

5.  Genomic islands of uropathogenic Escherichia coli contribute to virulence.

Authors:  Amanda L Lloyd; Tiffany A Henderson; Patrick D Vigil; Harry L T Mobley
Journal:  J Bacteriol       Date:  2009-03-27       Impact factor: 3.490

6.  Genetic profiles of fluoroquinolone-resistant Escherichia coli isolates obtained from patients with cystitis: phylogeny, virulence factors, PAIusp subtypes, and mutation patterns.

Authors:  Akira Takahashi; Tetsuro Muratani; Mitsuru Yasuda; Satoshi Takahashi; Koichi Monden; Kiyohito Ishikawa; Hiroshi Kiyota; Soichi Arakawa; Tetsuro Matsumoto; Hiroki Shima; Hisao Kurazono; Shingo Yamamoto
Journal:  J Clin Microbiol       Date:  2009-01-21       Impact factor: 5.948

7.  Virulence factors in urinary Escherichia coli strains: phylogenetic background and quinolone and fluoroquinolone resistance.

Authors:  Gabriella Piatti; Alessandro Mannini; Maria Balistreri; Anna Maria Schito
Journal:  J Clin Microbiol       Date:  2007-12-05       Impact factor: 5.948

8.  Major differences exist in frequencies of virulence factors and multidrug resistance between community and nosocomial Escherichia coli bloodstream isolates.

Authors:  Niamh M Cooke; Stephen G Smith; Mary Kelleher; Thomas R Rogers
Journal:  J Clin Microbiol       Date:  2010-01-27       Impact factor: 5.948

9.  Escherichia coli-mediated impairment of ureteric contractility is uropathogenic E. coli specific.

Authors:  Rachel V Floyd; Mathew Upton; Scott J Hultgren; Susan Wray; Theodor V Burdyga; Craig Winstanley
Journal:  J Infect Dis       Date:  2012-09-21       Impact factor: 7.759

10.  Community faecal carriage of extended-spectrum beta-lactamase-producing Enterobacteriaceae in French children.

Authors:  André Birgy; Robert Cohen; Corinne Levy; Philippe Bidet; Céline Courroux; Mohamed Benani; Franck Thollot; Edouard Bingen
Journal:  BMC Infect Dis       Date:  2012-11-21       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.